We’ve talked a lot about Big Pharma’s cost-cutting efforts : selling off or closing manufacturing plants, laying off sales reps, consolidating R&D. But the cuts aren’t limited to those functions. Administrative departments are shrinking, too. Just witness the latest from GlaxoSmithKline’s human resources operations. Glaxo is restructuring HR, aiming…

Outsourcing has been on an upswing for the past several years. Drugmakers have farmed out everything from research and manufacturing to IT and sales–and there are no signs that the move will let up this year. Eli Lilly just yesterday said it would outsource more of its R&D, and…

Drug companies talk a lot about recouping R&D costs when pricing meds, but let’s face it: Pharma is a for-profit business, usually with shareholders to satisfy. So profit is key, and profit margins are a closely watched measure. Now, thanks to Sanford Bernstein

Luitpold Pharmaceuticals, Inc., a New York based U.S. Company of Daiichi Sankyo Co., Ltd. (Corporate Headquarters: Tokyo, Japan) and PharmaForce, Inc., (Columbus, Ohio, USA), a privately-held fullyintegrated specialty injectable pharmaceutical company, announced today that PharmaForce has been acquired by Luitpold.

Original Source of Luitpold Pharmaceuticals, Inc. Acquires PharmaForce, Inc.

Patients with mental illness often aren’t getting treatments that are “just right.” In fact, recent studies show that too many patients are either

France’s approach to an over-abundance of H1N1 flu vaccine has stirred up fears–and critics. As we reported yesterday, France is trying to sell off millions of doses to countries in the Middle East and Latin America. It’s also looking to cancel orders for 50 million more doses. Yep, that’s…

Merck’s Schering-Plough unit

Help Wanted: CEO and president for a biotech company facing safety issues with a key drug. Skills required: All the usual ones, plus the ability to face occasional battles with activist investor Carl Icahn. Apply to Biogen Idec now. Yes, Biogen’s CEO and President James Mullen ( photo )…

Novartis may have thought it had Alcon in the bag, but the eye-care company’s board is objecting. Not to the Nestle deal; that is in the bag. It’s the offer Novartis made to minority shareholders worth $147 a share–less than the $180 per that Nestle’s getting for its stock….

Genzyme has tapped Hospira for help with manufacturing while it cleans up its act at a troubled plant. The outsourcing deal is aimed at alleviating shortages of two key drugs–partly to keep competitors from getting too much of a toehold in the market–and in the process, shoring up sales…